Jump to content
Sclero Forums

Search the Community

Showing results for tags 'skin fibrosis'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 30 results

  1. Increased expression of GAB1 promotes inflammation and fibrosis in systemic sclerosis (SSc). This data suggests that GAB1 has a relatively high expression rate in SSc, and knockdown of GAB1 may attenuate SSc by stimulating inflammatory and fibrotic processes. PubMed, Exp Dermatol, 09/10/2019. (Also see Prognosis and Mortality and Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. IL-16 expression is increased in the skin and sera of patients with systemic sclerosis. The regional up-regulation of IL-16 in the skin is not only associated with skin sclerosis, but also with systemic IL-16 activation. PubMed, Rheumatology (Oxford), 08/03/2019. (Also see Skin Fibrosis and Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. CCL3, IL-7, IL-13 and IFNγ transcripts are increased in skin's biopsy of systemic sclerosis (SSc). These molecules are involved in the pathogenesis of SSc, and how their interactions occur should be the subject of further studies. PubMed, Exp Dermatol, 06/04/2019. (Also see Skin Fibrosis and Cytokines) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Interleukin-17 pathways in systemic sclerosis–associated fibrosis. There is multitude of evidence from across different tissues that interleukin-17 (IL-17) and its downstream pathways are strongly associated with the initiation and propagation of fibrosis. PubMed, Rheumatol Int, 05/09/2019. (Also see Interleukins and Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. An extended high–frequency ultrasound protocol for assessing and quantifying of inflammation and fibrosis in localized scleroderma (LoS). High–frequency ultrasound allows an accurate assessment of the inflammatory and fibrotic skin lesions in LoS. PubMed, Skin Res Technol, 01/14/2019. (Also see Skin Fibrosis and Localized Scleroderma) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score (mRSS) in patients with systemic sclerosis. New EUSTAR standardized mRSS training significantly enhanced mRSS accuracy, especially in participant with less previous experience in skin scoring. PubMed, Int J rheumatologist Dis, 11/05/2018. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. CCN proteins as potential actionable targets in scleroderma (SSc). We discuss the possible implication of CCN proteins in SSc pathogenesis, with a special focus on skin features, and identify the potential actionable CCN targets. PubMed, Exp Dermatol, 10/17/2018. (Also see Causes of Scleroderma and Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. High–frequency ultrasound (HFU) of the skin in systemic sclerosis (SSc): an exploratory study to examine correlation with disease activity and to define the minimally detectable difference. In the study, HFU was able to measure skin thickness, it correlated quantitatively with a valid measure of SSc activity, and a minimal detectable difference was identified. PubMed, Arthritis Res Ther, 2018 Aug 16;20(1):181. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. The results suggest that systemic scleroderma patients with high TLR4 activity might show optimal therapeutic response to selective inhibitors of MD2/TLR4 complex formation. PubMed, JCI Insight, 2018 Jul 12;3(13). (Also see Fibroblasts, Skin Fibrosis and Pulmonary Fibrosis Research) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Adipocyte–specific Repression of PPAR-gamma by NCoR Contributes to Scleroderma Skin Fibrosis. Our results implicate, for the first time, to our knowledge, deregulated NCoR/PPAR-γ pathways in SSc, and they support a role of adipocyte modulation of skin fibrosis. BMC, Arthritis Research & Therapy, 07/11/2018. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Skin gene expression of biomarkers may provide guidance in decision–making about which patients should be considered for aggressive therapies and/or for clinical trials. PubMed, Arthritis Rheumatol, 2018 Jun;70(6):912-919. (Also see Diffuse Scleroderma and Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Methyl-CpG-binding protein 2 (MeCP2) mediates antifibrotic effects in scleroderma (SSc) fibroblasts. This study demonstrates a novel role for MeCP2 in skin fibrosis and identifies MeCP2-regulated genes, which can be potentially targeted for therapy in SSc. PubMed, Ann rheumatologist Dis, 05/14/2018. (Also see Fibroblasts and Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. Do scleroderma patients look young?: Evaluation by using facial imaging system. The severity of wrinkles, texture and pores were significantly lower in SSc patients than control subjects and among them, wrinkles showed better correlation with skin thickness score. PubMed, Drug Discov Ther, 2017;11(6):342-345. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. The roles of dermal white adipose tissue (DWAT) loss in scleroderma skin fibrosis. The loss of skin–protective mechanisms with DWAT loss further contributes to skin fibrosis and injury. PubMed, Curr Opin Rheumatol, 08/10/2017. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  15. Quantitative Assessment of Skin Stiffness in Localized Scleroderma (LS) Using Ultrasound Shear–Wave Elastography. This non–invasive, real–time imaging technique is an ideal tool for assessing and monitoring LS disease severity and progression. PubMed, Ultrasound Med Biol, 04/27/2017. (Also see Localized Scleroderma and Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  16. Cell Therapy for Localized Scleroderma Can Reverse Fibrosis in Mice. A cell therapy based on injected genetically modified human skin cells and a pill that activates a protein has the capacity for breaking down fibrosis in localized scleroderma c–at least in mice. Scleroderma News, 05/11/2017. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  17. CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis (SSc). These results suggest that CD16+ monocytes are associated with the main fibrotic manifestations of SSc and their role in the pathogenesis of fibrosis in this autoimmune disorder should therefore be further considered. PubMed, Clin Rheumatol, 03/14/2017. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  18. Topical Scleroderma Medicine Seen to Lessen Fibrosis and Inflammation in Mouse Model. A new topical medicine, called SM04755, significantly decreased and even reversed fibrosis and inflammation in in vitro and in vivo mouse studies of scleroderma. Scleroderma News, 11/08/2016. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  19. Pan peroxisome proliferator–activated receptors (PPAR) agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. These findings indicate that simultaneous activation of all three PPAR isoforms exerts a dampening effect on inflammation and fibrosis, making IVA337 a potentially effective therapeutic candidate in the treatment of fibrotic diseases including SSc. PubMed, Ann rheumatologist Dis, 2016 Dec;75(12):2175-2183. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  20. A personalized physical therapy program or usual care for patients with systemic sclerosis (SSc): A randomized controlled trial. A personalized physical therapy program did not reduce disability at 12 months but had short–term benefits for patients with SSc. PubMed, Arthritis Care Res (Hoboken), 10/12/2016. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  21. An Autotaxin–LPA–IL–6 Amplification Loop Drives Scleroderma (SSc) Fibrosis. Results suggest that concurrent inhibition of two pathways, LPA and IL–6, may be an effective therapeutic strategy for SSc fibrosis. PubMed, Arthritis Rheumatol, 07/07/2016. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  22. Scleroderma Mouse Study Suggests Estrogen Therapy Might Slow Skin Fibrosis. The study confirmed that estrogens play a role in protecting against skin fibrosis in experimental models representative of systemic sclerosis and the next step will be to begin investigating the potential role of hormone therapies as a treatment. Scleroderma News, 06/13/2016. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  23. M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo. M10 peptide interacts with Smad2 and demonstrates strong antifibrotic effects in vitro and in vivo in an animal model of lung fibrosis and should be considered as a potential therapeutic agent for systemic sclerosis and other fibrosing diseases. PubMed, Transl Res, 2016 Apr;170:99-111. (Also see Skin Fibrosis and Pulmonary Fibrosis) This item was posted in the ISN Newsroom Please check the newsroom daily for updates on scleroderma and other related articles.
  24. Self–assessment of skin tightness severity by scleroderma patients. The respective modified Rodnan skin score assessment by patient versus the physician was highly correlated with a high level of agreement. PubMed, Int J rheumatologist Dis, 04/29/2016. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom Please check the newsroom daily for updates on scleroderma and other related articles.
  25. Effect of endothelin–1 receptor antagonists (ETRAs) on skin fibrosis in scleroderma (SSc) patients from the EUSTAR database. ETRAs have well–proven clinical effects in the prevention of digital ulcers and in the treatment of pulmonary hypertension, but there is no evidence from clinical studies to support its use as an anti–fibrotic therapy. Journal of Scleroderma and Related Disorders, 03/30/2016. (Also see Skin Fibrosis and Endothelin and Systemic Scleroderma) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...